US 12,354,130 B2
Combination therapies
Gordon Bray, San Francisco, CA (US); and Iris Chan, San Francisco, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Aug. 17, 2023, as Appl. No. 18/451,452.
Application 18/451,452 is a continuation of application No. 17/444,691, filed on Aug. 9, 2021, granted, now 11,783,366.
Application 17/444,691 is a continuation of application No. 13/967,782, filed on Aug. 15, 2013, granted, now 11,087,354, issued on Aug. 10, 2021.
Claims priority of provisional application 61/780,708, filed on Mar. 13, 2013.
Claims priority of provisional application 61/722,725, filed on Nov. 5, 2012.
Claims priority of provisional application 61/706,026, filed on Sep. 26, 2012.
Claims priority of provisional application 61/705,575, filed on Sep. 25, 2012.
Claims priority of provisional application 61/684,673, filed on Aug. 17, 2012.
Prior Publication US 2024/0046303 A1, Feb. 8, 2024
Int. Cl. A61K 31/397 (2006.01); A61K 31/375 (2006.01); A61K 31/437 (2006.01); A61K 31/4523 (2006.01); A61P 17/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C12Q 1/6886 (2018.01); G06Q 30/0241 (2023.01)
CPC G06Q 30/0241 (2013.01) [A61K 31/437 (2013.01); A61K 31/4523 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01)] 5 Claims
 
1. An article of manufacture, the article of manufacture comprising a container comprising (a) a first composition comprising 60 mg of [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl]methanone, or a pharmaceutically acceptable salt thereof, provided as a tablet and (b) a second composition comprising 960 mg of propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo [2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, provided as a tablet.